Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)

Author:

Gheorghiade Mihai,Orlandi Cesare,Burnett John C.,DeMets David,Grinfeld Liliana,Maggioni Aldo,Swedberg Karl,Udelson James E.,Zannad Faiez,Zimmer Christopher,Konstam Marvin A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. 2001 National Hospital Discharge Survey. Advance data from vital and health statistics;Hall,2003

2. Annual rates of admission and seasonal variations in hospitalizations for heart failure;Martinez-Selles;Eur J Heart Fail,2002

3. ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure;Fonarow;Rev Cardiovasc Med,2003

4. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure;Lucas;Am Heart J,2000

5. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial;Gattis;J Am Coll Cardiol,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3